• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较病毒基疟疾疫苗试验中人类 T 细胞和 NK 细胞的反应。

Comparing human T cell and NK cell responses in viral-based malaria vaccine trials.

机构信息

Centre for Clinical Vaccinology and Tropical Medicine, Oxford University, Churchill Hospital, Oxford, UK.

出版信息

Vaccine. 2009 Dec 10;28(1):21-7. doi: 10.1016/j.vaccine.2009.09.132. Epub 2009 Oct 17.

DOI:10.1016/j.vaccine.2009.09.132
PMID:19837090
Abstract

Vaccination with viral-based vaccines continues to hold promise for the prevention of malaria. Whilst antigen-specific T cell responses are considered a major aim of such an approach, a role for induced NK cells as anti-malarial effector cells, or in shaping T cell responses, has received less attention. In this study naïve human volunteers were vaccinated in a prime-boost vaccination regimen comprising recombinant viral vectors fowlpox (FP9) and modified vaccinia Ankara (MVA) encoding liver-stage antigens, or a virosome vaccine. Significant T cell responses specific for the vectored vaccine antigens were demonstrated by IFNgamma ELISPOT and intracellular cytokine staining (ICS) for IFNgamma and IL-2, the ICS being associated with increased time to parasitaemia following subsequent challenge. Numbers of CD56(bright) lymphocytes increased significantly following vaccination, as did CD3(+) CD56(+) lymphocytes, whilst CD56(dim) cells did not. No such increases were seen with the virosome vaccine. There was no significant correlation of these CD56(+) populations with the antigen-specific T cell responses nor time to parasitaemia. To investigate pathways of immune activation that could contribute to these lymphocyte responses, viral vectors were shown in vitro to efficiently infect APCs but not lymphocytes, and stimulated inflammatory cytokines such as type I interferons. In conclusion, measuring antigen-specific T cells is more meaningful than NK cells in these vaccination regimens.

摘要

基于病毒的疫苗接种在预防疟疾方面仍然具有很大的潜力。虽然抗原特异性 T 细胞反应被认为是这种方法的主要目标,但诱导的 NK 细胞作为抗疟效应细胞,或在塑造 T 细胞反应方面的作用,受到的关注较少。在这项研究中,将 naive 人类志愿者用包含编码肝期抗原的重组病毒载体禽痘病毒(FP9)和改良安卡拉痘苗(MVA)的初免-加强疫苗方案,或病毒体疫苗进行接种。通过 IFNγ ELISPOT 和 IFNγ 和 IL-2 的细胞内细胞因子染色(ICS),证明了针对载体疫苗抗原的显著 T 细胞反应,ICS 与随后的寄生虫血症挑战后寄生虫血症时间的增加相关。接种后 CD56(明亮)淋巴细胞数量显著增加,CD3(+)CD56(+)淋巴细胞数量也增加,而 CD56(暗淡)细胞没有增加。病毒体疫苗没有观察到这种增加。这些 CD56(+)群体与抗原特异性 T 细胞反应或寄生虫血症时间没有显著相关性。为了研究可能有助于这些淋巴细胞反应的免疫激活途径,研究表明,病毒载体在体外可以有效地感染 APC 但不能感染淋巴细胞,并刺激炎症细胞因子,如 I 型干扰素。总之,在这些疫苗接种方案中,测量抗原特异性 T 细胞比 NK 细胞更有意义。

相似文献

1
Comparing human T cell and NK cell responses in viral-based malaria vaccine trials.比较病毒基疟疾疫苗试验中人类 T 细胞和 NK 细胞的反应。
Vaccine. 2009 Dec 10;28(1):21-7. doi: 10.1016/j.vaccine.2009.09.132. Epub 2009 Oct 17.
2
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.通过使用重组痘病毒FP9和改良安卡拉痘苗病毒,增强T细胞介导的对人类疟疾攻击的保护作用。
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41. doi: 10.1073/pnas.0406381102. Epub 2005 Mar 21.
3
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.重组鸡痘病毒株FP9和改良安卡拉痘苗病毒疫苗在非免疫志愿者中针对恶性疟原虫肝期疟疾的安全性。
Vaccine. 2006 Apr 5;24(15):3026-34. doi: 10.1016/j.vaccine.2005.10.058. Epub 2006 Feb 2.
4
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.对3种高免疫原性的初免-加强免疫方案(包括12个月后的再次加强免疫接种)在冈比亚男性中进行疟疾疫苗接种的1期评估。
J Infect Dis. 2004 Jun 15;189(12):2213-9. doi: 10.1086/421118. Epub 2004 May 24.
5
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.使用佐剂Matrix-M™的病毒载体疟疾疫苗进行异源初免-加强免疫的安全性和免疫原性
Vaccine. 2017 Oct 27;35(45):6208-6217. doi: 10.1016/j.vaccine.2017.09.028. Epub 2017 Sep 21.
6
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.在健康志愿者中使用DNA和病毒载体的各种异源初免-加强疫苗方案的差异免疫原性。
J Immunol. 2005 Jan 1;174(1):449-55. doi: 10.4049/jimmunol.174.1.449.
7
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.评估新型疫苗接种方案,使用编码 ME-TRAP 的病毒载体肝脏阶段疟疾疫苗。
Sci Rep. 2018 Feb 21;8(1):3390. doi: 10.1038/s41598-018-21630-4.
8
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.在 ChAd63 和 MVA 疫苗载体中评估恶性疟原虫血期抗原 AMA1 的安全性和免疫原性的 I 期临床研究。
PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.
9
A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.一种基于重组痘病毒编码的六抗原多聚蛋白的恶性疟原虫候选疫苗。
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):290-5. doi: 10.1073/pnas.0307158101. Epub 2003 Dec 23.
10
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.重组改良安卡拉痘苗病毒增强的质粒DNA疫苗在人体内的T细胞免疫原性增强。
Nat Med. 2003 Jun;9(6):729-35. doi: 10.1038/nm881. Epub 2003 May 25.

引用本文的文献

1
Dynamic Changes in Natural Killer Cell Subset Frequencies in the Absence of Cytomegalovirus Infection.自然杀伤细胞亚群频率在无巨细胞病毒感染时的动态变化。
Front Immunol. 2019 Nov 22;10:2728. doi: 10.3389/fimmu.2019.02728. eCollection 2019.
2
Vaccinating for natural killer cell effector functions.针对自然杀伤细胞效应功能进行疫苗接种。
Clin Transl Immunology. 2018 Jan 31;7(1):e1010. doi: 10.1002/cti2.1010. eCollection 2018.
3
TB vaccine development and the End TB Strategy: importance and current status.结核病疫苗研发与终结结核病战略:重要性及现状
Trans R Soc Trop Med Hyg. 2016 Apr;110(4):212-8. doi: 10.1093/trstmh/trw016.
4
Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.婴儿接种MVA85A疫苗前及接种后一天的炎症和髓系相关基因表达与T细胞反应的诱导相关。
BMC Infect Dis. 2014 Jun 9;14:314. doi: 10.1186/1471-2334-14-314.
5
Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.新型重组猿猴腺病毒 ChAdOx1 作为表达保守型流感 A 抗原的载体疫苗的临床评估。
Mol Ther. 2014 Mar;22(3):668-674. doi: 10.1038/mt.2013.284. Epub 2013 Dec 30.
6
A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.一种用于老年人的 T 细胞诱导型流感疫苗:MVA-NP+M1 在 50 岁以上成年人中的安全性和免疫原性。
PLoS One. 2012;7(10):e48322. doi: 10.1371/journal.pone.0048322. Epub 2012 Oct 31.
7
Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.抗原特异性白细胞介素 2 分泌与坦桑尼亚儿童接种 RTS,S/AS01 疟疾疫苗后的 NK 细胞反应相关。
J Immunol. 2012 May 15;188(10):5054-62. doi: 10.4049/jimmunol.1102710. Epub 2012 Apr 13.
8
A molecular assay for sensitive detection of pathogen-specific T-cells.一种用于敏感检测病原体特异性 T 细胞的分子检测方法。
PLoS One. 2011;6(8):e20606. doi: 10.1371/journal.pone.0020606. Epub 2011 Aug 11.
9
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.新型异源型流感 A 疫苗 MVA-NP+M1 在人体中具有强大的 CD8+ T 细胞免疫原性。
Clin Infect Dis. 2011 Jan 1;52(1):1-7. doi: 10.1093/cid/ciq015.